In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a
coronavirus infection, or a COVID-19 infection, or an infection caused by a
virus in the
subfamily Orthocoronavirinae, or a
virus in the family
Coronaviridae, or a
virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a
drug or drugs as provided herein are administered either enterally, parenterally and / or by
inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block
intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel
aerosol, spray or mist or
powder formulations for
inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a
drug, a pharmaceutical
dosage form, a
drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and / or inhaled
chloroquine (or ARALEN™),
chloroquine phosphate,
chloroquine diphosphate and / or
hydroxychloroquine (optionally, PLAQUENIL™), with or without
azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™),
chloroquine phosphate, chloroquine diphosphate and / or
hydroxychloroquine (optionally, PLAQUENIL™), and / or
azithromycin, and others, are in or formulated as a formulation for
inhalation, for example, formulated as an
aerosol, spray, mist, liquid or
powder.